Von Willebrand disease (VWD) is a complex and fascinating bleeding disorder that has puzzled medical professionals for nearly a century. It was first identified by Erik von Willebrand in 1926, who studied a family with a new type of bleeding disorder. Little did he know that this discovery would lead to the recognition of the most frequent inherited hemorrhagic disorder, affecting approximately 1% of the population. But here's where it gets controversial: despite its high prevalence, VWD remains a challenging condition to diagnose and manage, especially in mild cases. This article delves into the classification, epidemiology, and clinical aspects of VWD, shedding light on the complexities and controversies surrounding this intriguing disorder.
VWD is caused by reduced levels or activity of von Willebrand factor (VWF), a protein essential for blood clotting. The disease is highly heterogeneous, presenting with a wide range of clinical and laboratory phenotypes. Diagnosis is based on three main criteria: a positive bleeding history, low levels of circulating VWF, and autosomal inheritance patterns. VWD is classified into two main types: quantitative VWF deficiencies (type 1 and type 3) and qualitative defects (type 2). Type 1 VWD is the most common, with partial VWF deficiency, while type 3 is rare and characterized by almost total VWF deficiency.
The prevalence of VWD is estimated to be around 1% in the general population, but this figure is not without controversy. Epidemiological investigations have suggested that the prevalence could be as high as 1%, but a clear-cut diagnosis is often challenging due to confounding factors influencing plasma VWF levels, especially in mild cases. The prevalence of clinically relevant VWD is estimated to range from 1/1,000 to 10,000 inhabitants, but this estimate is based on patients referred to tertiary care centers, which may not represent the true prevalence in the general population.
The clinical presentation of VWD varies widely, with patients experiencing excessive mucocutaneous bleeding, including epistaxis, gum bleeding, heavy menstrual bleeding, and gastrointestinal bleeding. The severity of bleeding correlates with the degree of VWF and factor VIII reduction, with some mucocutaneous bleeding being rather frequent and affecting the quality of life. However, the rate of spontaneous bleeding can be low even in patients with significant VWF deficiency.
The classification of VWD is further complicated by the presence of different subtypes within each type. For instance, type 2 VWD is divided into four variants based on distinct pathophysiological mechanisms and laboratory features. Type 2A is caused by VWF variants that decrease binding to platelet glycoprotein Ib (GPIb) receptor, while type 2B shows a spontaneous increased affinity for platelet GPIb receptor, leading to persistent thrombocytopenia. Type 2M and 2N have distinct binding abnormalities to GPIb and factor VIII, respectively.
The prevalence of VWD varies across different types and subtypes, with type 3 being the rarest and type 1 being the most common. The prevalence of severe VWD, such as type 3, is very low, ranging from 0.1 to 5.3 per million in the population. However, the prevalence of intermediate and mild VWD is less certain, with estimates ranging from 40 to 100 cases per million for intermediate VWD and one case per 1,000 to 10,000 subjects for mild VWD.
The diagnosis of VWD is further complicated by the limitations of current diagnostic tools and the lack of awareness among non-expert clinicians. Genetic testing has limited diagnostic value in mild type 1 VWD, while it remains useful in other types. The use of stringent clinical criteria and standardized questionnaires is crucial to achieve accurate assessment and inter-observer reproducibility. However, potential pitfalls may arise in prevalence estimates due to the clinical presentation of VWD, with hospital-based investigations often resulting in lower prevalence figures than population-based investigations.
In summary, VWD is a highly heterogeneous bleeding disorder with a complex classification and epidemiology. The prevalence of clinically significant cases is uncertain, and many borderline cases remain undiagnosed or receive a delayed diagnosis. The current diagnostic pathways need improvement, and more efforts should be made to increase awareness, establish registries, and organize clinical prospective observations to determine the frequency and severity of bleeding events, especially in patients with moderate and mild VWD. And this is the part most people miss: VWD is a prime example of how a seemingly straightforward disease can present a myriad of challenges in diagnosis and management, highlighting the importance of continued research and clinical vigilance.
